Close this search box.

The Institute for Clinical and Economic Review says new CGRP inhibitor treatments for chronic and episodic migraine probably won’t be cost effective. But the analysis omits five important components.

View the Graphic

Leave a Reply

Your email address will not be published. Required fields are marked *